Geniculate Ganglion Tumors: Clinical Presentation and Surgical Results

Ghizlene Lahlou, Yann Nguyen, Francesca Yoshie Russo, Evelyne Ferrary, Olivier Sterkers, Daniele Bernardeschi

► To cite this version:

Ghizlene Lahlou, Yann Nguyen, Francesca Yoshie Russo, Evelyne Ferrary, Olivier Sterkers, et al.. Geniculate Ganglion Tumors: Clinical Presentation and Surgical Results. Otolaryngology - Head and Neck Surgery, 2016, 155 (5), pp.850 - 855. 10.1177/0194599816661482 . hal-01396682

HAL Id: hal-01396682

<https://hal.sorbonne-universite.fr/hal-01396682>

Submitted on 14 Nov 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title:

**GENICULATE GANGLION TUMORS: CLINICAL PRESENTATION AND
SURGICAL RESULTS.**

Authors

Ghizlene LAHLOU^{1,2,3}, MD

Yann NGUYEN^{1,2,3}, MD, PhD

Francesca Yoshie RUSSO^{1,2,3}, MD

Evelyne FERRARY^{1,2,3}, MD, PhD

Olivier STERKERS^{1,2,3}, MD, PhD

Daniele BERNARDESCHI^{1,2,3}, MD, PhD

1. AP-HP, Pitie-Salpetriere Hospital, Otology, auditory implants and skull base surgery
department, 75013, Paris, France
2. Sorbonne Universités, UPMC Univ Paris 06, F-75005, Paris, France
3. INSERM UMR_S 1159, « Mini-invasive and robot-based surgical rehabilitation of
hearing», F-75018 France

Corresponding author:

Daniele Bernardeschi, MD, PhD

Unité Otologie, Implants auditifs et Chirurgie de la base du crâne – Hôpital Pitie-Salpetriere
50/52 Boulevard Vincent Auriol - 75013 – Paris – France

Tel: +33 (0)1 42 16 26 03 / Fax : + 33 (0)1 42 16 26 05

E-mail : daniele.bernardeschi@aphp.fr

Keywords: Geniculate ganglion; hemangioma; schwannoma; meningioma; facial nerve graft

27 **Abstract**

28 *Objective.* Facial nerve tumors are rare lesions mostly located in the geniculate ganglion. This
29 study aims to compare those tumors limited to the geniculate ganglion in terms of clinical
30 features and postoperative outcomes.

31 *Study Design.* Case series with chart review.

32 *Settings.* University tertiary reference center.

33 *Subjects and Methods.* Medical charts of 17 patients operated on for a geniculate ganglion
34 tumor removal (10 hemangiomas, 6 schwannomas, one meningioma) were reviewed.
35 Hemangiomas and schwannomas were compared for preoperative facial nerve function,
36 hearing, tumor size, and postoperative outcomes.

37 *Results.* Facial palsy was observed in all cases. Regarding the preoperative facial nerve
38 function, severe facial palsy (House-Brackmann grade V and VI) was present in 70% of cases
39 for hemangiomas and for no case of schwannoma ($p = 0.01$), although hemangiomas were
40 significantly smaller tumors ($p=0.01$). Hearing loss was observed in 4 cases (23.5%), and was
41 related to tumor volume ($p<0.0001$). A complete excision was achieved in all cases, and a
42 facial nerve graft was performed immediately after interruption in 16 patients (94%).
43 Postoperative facial nerve function was improved or stabilized in 94% of cases. A
44 preoperative House-Brackman grade VI was shown as a negative factor for postoperative
45 facial nerve function.

46 *Conclusions.* Differences in clinical presentations could help in establishing the good
47 therapeutic option depending on the tumor type. Sugery, when indicated, is safe and effective,
48 and postoperative outcomes are not related to tumor type.

49

INTRODUCTION

Facial nerve (FN) tumors are rare lesions of the petrous bone.¹ They include schwannomas, hemangiomas, and meningiomas. Schwannomas represent 0,8% of petrous bone tumors.² It is a benign, encapsulated, slow growing lesion arising from the Schwann cells, that can involve any of the different segments of the FN, the geniculate ganglion (GG) being the most frequent segment involved.³ FN hemangiomas encompass 0.7% of petrous bone tumors⁴ and they have been nowadays reclassified in the group of vascular malformations.⁵ As schwannomas, hemangiomas are mainly located in the GG.⁵ FN meningiomas are an extremely rare tumor, with only some case reports reported in the literature.^{6,7} They arise from arachnoid cells accompanying the FN during its embryonic formation.⁸ The GG and the internal auditory canal are the two preferential locations of petrous bone meningiomas.⁷

When the tumor is limited to the GG, the most common symptom is facial paralysis. Even if the radiological features of these lesions (MRI and CT-scan) might help in the differential diagnosis, no study has been done to analyze differences in clinical presentation among the different tumor types that could help in establishing a correct preoperative diagnosis. This is nowadays essential in order to define the correct management of these tumors considering the increasing number of patients affected by FN schwannoma treated with stereotaxic radiosurgery.⁹

Thus, the aim of this study was to compare the different tumor types of GG tumors in regards to their preoperative clinical features and postoperative results.

Methods

Medical records of patients operated on for an intrapetrous FN tumor from 1988 to 2013 period in a tertiary referral center were retrospectively reviewed. All patients gave their informed consent for the use of their clinical data, and the ethics committee of Pitie-Salpetriere hospital approved the study. All the patients were operated on and evaluated by the same senior surgeon (OS), for preoperative and postoperative features, because he was the only physician present for the entire duration of the inclusion period, and the most experienced one for FN tumor cases.

Inclusion criteria were an isolated GG tumor on the basis of imaging and post-operative histological examination. Tumors located in another segment of the FN or spreading from the GG to another segment were excluded. Non-primary FN tumors involving the petrous bone with extension to GG (metastasis, cholesteatomas) were also excluded. Patients with a diagnosis of type II neurofibromatosis were excluded because of the risk of multiple lesions involving the FN. The tumor type was confirmed by histological examination after tumor excision. Frozen sections of the facial nerve at proximal (labyrinthine) and distal (tympanic) segment of the FN were performed in all but one patient who underwent tumor excision without interruption of the FN.

Pre-operative Assessment

The data at the first consultation included demographic information, presenting symptoms, facial function according to the House and Brackman (HB) scale,¹⁰ the mean pure-tone audiometry (PTA) (mean of 500,1000, 2000 and 3000 Hz) in air and bone conduction with headphones, hearing classification according to AAO-HNS, and vestibular function evaluated by a caloric test. A vestibular impairment was defined as a lateralization and a directional preponderance more than 25% calculated by Jongkee's formula. Imaging (CT scan and magnetic resonance imaging – MRI - in T1-WI, T2-WI, and T1 with contrast) was available

for all patients and was analysed for tumor size on the post-contrast T1-WI sequences, and the presence of cochlear or labyrinthine fistula on CT-scan and T2-WI.

Peri- and Post-operative Data

Perioperative data included surgical approach, and, in case of interruption of the FN, the type of reconstruction of the nerve.

Postoperative data included complications, FN function at 12 months and at the last consultation, auditory outcomes, and recurrences detected by MRI studies performed every year after surgery in the three first postoperative years of follow-up (FU).

Statistical Analysis

Results are presented as mean $\pm$ standard deviation (SD). Hemangiomas and schwannomas were compared using Fisher tests for qualitative data; Wilcoxon tests, Kruskal-Wallis tests and Pearson tests for quantitative data. Statistical tests were performed using R (version 3.2.3). Differences were considered statistically significant when $p < 0.05$.

Results

Patients

Seventeen patients were included in this study (**Table 1**). They were affected by hemangioma in 10 cases (59%), schwannoma in 6 cases (35%) and meningioma in one case (6%). The mean age was 43 ± 12.9 years (range = 22 - 68). The tumours were located in the right temporal bone in 8 cases (47%) and in the left in 9 cases (53%). There was no difference between the groups in side of the tumor, sex or age (Fisher and Wilcoxon tests).

Preoperative Data

All patients presented some degree of facial impairment as first symptoms. The overall facial function was grade II in one case (6%), grade III in one case (6%), grade IV in 8 cases (47%), grade V in 4 cases (23.5%), and grade VI in three cases (17.5%). Preoperative FN function was not related to tumor size, to patient age, or to preoperative duration of facial palsy (Kruskall-Wallis test). However, severe FN palsy (grade V or VI) was observed only in hemangioma cases: 7 patients with hemangioma (70%) had a HB V or VI and no patients with schwannoma ($p=0.01$, Fisher test – **Table 2**)

The pattern of the facial palsy was progressive in 11 cases (65%), sudden for 4 patients (23.5%), and recurrent in two cases (12%). There was no significant difference between these different modes of evolution depending on the type of tumor (Fisher test, data not shown).

Regarding the hearing status, an overall hearing impairment was present in 4 cases (23.5%), which were three schwannomas and one hemangioma, which were three cases of sensorineural hearing losses and one case of conductive hearing loss. The PTA was significantly higher in case of schwannoma compared to hemangioma ($p=0.007$ – Wilcoxon test, **Table 2**) but a significant correlation between tumor size and PTA was found (Pearson test, $r=0.8$, $p<0.0001$).

There was no difference in vestibular impairment depending on tumor type (**Table 2**) or tumor size (Fisher test).

Regarding the size of the tumor (**Table 2**), hemangiomas were significantly smaller compared to schwannomas: the mean diameter was 8 ± 3.7 mm and 16 ± 7.3 mm for hemangioma and schwannoma respectively ($p=0.01$ – Wilcoxon test). Two patients had a pre-operative cochlear fistula identified on pre-operative imaging studies (case 12 and 16, **table 1**).

Surgery

Regarding the surgical approach, the middle cranial fossa was used in all cases. Computer-assisted surgical navigation¹¹ and the facial nerve stimulating burr¹² were used since 2007

and 2010 respectively. A total tumor resection was achieved in all cases; the FN was interrupted and immediately repaired in 16 patients (94%), using a great auricular nerve graft in 15 cases and a sural nerve graft (due to the small diameter of the great auricular nerve) in one case. One patient (6%) underwent a total resection of a GG schwannoma with an anatomically intact FN at the end of the procedure. In this particular case, a good dissection plane could be found easily and the tumor could be separated for the FN (case 14, **table 1**).

Postoperative Outcomes

There were no major complications: no temporal lobe injuries, no cerebro-spinal fluid leaks. One case of asymptomatic postoperative extradural hematoma with spontaneous resolution was observed.

The mean follow-up was 3.7 ± 2.99 years, range = 1 – 11 (n=16). One patient was lost to follow-up one month after surgery. At the last postoperative consultation, the overall facial function (n=16) was grade III in 11 cases (69%), grade IV in 4 cases (25%), and grade V in one case (6%). Facial function improved in 12 cases (75%), stabilized in 3 cases (19 %) and worsened in one case (6%) from a HB II to a HB III. Regarding hemangiomas and schwannomas' cases that had FN interruption with a FN graft (n= 14), the overall facial function at last postoperative consultation was grade III in 9 cases (64%), grade IV in 4 cases (29%), and grade V in one case (7%). Facial function improved in 10 cases (71%), stabilized in 3 cases (21 %) and worsened in one case (7%) from a HB II to a HB III. Severe synkinesis were reported for two patients (14%) who had a HB IV. There was no difference in FN outcomes comparing hemangioma cases to schwannoma cases (**Table 1**, Fisher test).

Patient's age, tumor size and duration of preoperative facial palsy were not related to FN function at 12 months postoperatively (Kruskall-Wallis test). Conversely, preoperative HB grade VI was significantly related to poorer post-operative FN function after FN grafting in patients operated for hemangioma or schwannoma (n=14): indeed, a worse postoperative FN

function (grade IV, V, VI) was present in all patients who had a preoperative HB VI (n=3), and only in 18% (n=2) of patients who had less severe preoperative FN function (n=11) (p=0.02 – Fisher test).

Regarding the hearing, it was preserved in 15 cases (94%) and worsened in one patient affected by a cochlear fistula from a class C to a class D (6%).

Post-operative MRI was available for 16 patients and no recurrence was detected in a yearly-performed MRI.

Discussion

This study demonstrates that, although the main symptom is facial palsy for all types of GG tumors, facial impairment is more severe in cases of hemangioma than in cases of schwannoma. Severe FN palsy in cases of hemangioma has already been reported in other studies,¹³⁻¹⁵ but this is the first study that compares these two tumor types.

Several hypotheses were highlighted in literature to explain the FN palsy in GG tumors: the compression by the growing tumor^{7,16} is certainly one of the main factors followed by the invasion of the nerve identified by histological analysis.¹⁴ Moreover, since hemangioma is a vascular malformation that develops from the rich venous plexus that surround the GG,¹⁷ some authors raised the hypothesis of a vascular steal that causes a facial palsy by an ischemic phenomenon for this type of tumor.¹⁸ This could account for the more severe FN impairment for hemangioma that is usually smaller at diagnosis compared to schwannoma, as already reported in other studies.^{13,19} These clinical differences, together with radiological features (**Table 3, Figure 1**), could help in making the correct diagnosis.

The present study describes only cases of total excision. It shows that postoperative outcomes did not depend on tumor histology for GG tumors. When surgery is indicated, the postoperative FN function improves in most of the patients with the majority of patients

reaching a postoperative HB grade III (64% of cases), which is in line with results reported on literature: from 55% to 86% of HB III after facial nerve grafting.²⁰⁻²² Synkinesis are very difficult to assess, but the low incidence of severe synkinesis in the present study could be explained by the use of short grafts, from labyrinthine to tympanic portion of the facial nerve (tumors located only on the geniculate ganglion), that could contribute to a more precise axonal regrowth. Only a preoperative HB grade VI doesn't provide a satisfactory recovery of the nerve. This has been already been pointed out in another studies.^{20,22} The complete tumor resection remains the curative treatment for GG tumors, and its indication depends on the preoperative facial nerve function.³ Indeed, since a FN interruption is necessary in most of the cases to achieve a complete resection, most of the authors advocate surgery when the FN function is at least HB III,^{3,20,21,23} or worse. A conservative approach with dissection of the FN was possible in one schwannoma as proposed by others.^{24,25} Such a result was not achieved for hemangiomas due to the tumor invasion of the FN,¹³ although some cases have been reported in literature.^{13,26} In case of meningioma, only one report with a dissection of the FN from the tumor has been published.²⁷

Regarding hearing, surgery allows hearing preservation in most of the cases through a middle cranial fossa approach, that is routinely used for GG tumors.^{15,17,19} As showed in this study, preoperative cochlear fistula could be associated to a worsening of hearing.^{13,14}

Other options can be proposed for the management of GG tumors. The first is the wait-and-scan strategy, which can be a good option in case of a non-growing poor symptomatic tumor, with a normal or near-normal FN function (HB I and II). These tumors are more frequently schwannomas than hemangiomas because of a more severe facial function in cases of hemangiomas as seen previously. In a review of 120 cases of GG hemangiomas, only 11 had been observed, and the facial function remained stable only for 28% of observed cases.¹⁵ The second option is a decompression surgery that aims to avoid the axonal lesions of the FN caused by the tumor compression in the Fallopian canal. Wilkinson et al reported an

improvement of the FN function in 16% of cases and a decrease in 21% of cases for 21 patients who had a decompression surgery for a FN schwannoma, with no difference in tumor's evolution between decompression and observation.²⁰ Decompression can be a good option when the tumor is confined in the Fallopian canal, but most of the time, when the tumor is located only on the GG, the bony roof has already been eroded by the tumor itself. Radiosurgery is a viable option in case of growing schwannoma of the GG with a FN function grade I or II. The goal of radiosurgery is to reduce or to stabilize the tumor volume and the facial nerve function. According to the literature, the tumor size is stabilized or reduced in 83% to 100% of patients, and FN function is improved or stabilized in 67% to 100% of patients.^{20,28-31} Regarding patients' hearing after radiosurgery, a meta-analysis of 14 patients treated with radiosurgery for FN schwannoma for whom the auditory data were available reported 36.7% of patients whose hearing worsened.⁹ Concerning hemangiomas, no studies have been yet published on the use of radiosurgery for these tumors. So, in case of preoperative GG tumors with a good preoperative FN function (grade I or II), in order to avoid unnecessary and ineffective treatment, establishing a correct diagnosis of the tumor type is fundamental because only schwannoma could be successfully treated with radiosurgery. In the other cases, wait-and-scan policy is a viable option. Limitations of the study include its retrospective nature, and the poor statistical power due to the small sample size. This is the result of GG tumor's scarcity. This also enables the ability to perform multivariate analysis for prognosis factors assessment. Finally, the assessment of FN function can be discussed because of the subjectivity of HB scale. Also, this scale is not a good scale for synkinesis and spasm evaluation, as a patient can be assessed on a HB III or IV regarding the severity of his spasms and synkinesis. Nevertheless, it is the more common scale used by neurotologists in literature, and results of this study are comparable to other postoperative outcomes in terms of FN function.^{20,21}

251 **Conclusion**

252 Hemangioma appears to be smaller in size but more aggressive on FN function than
253 schwannoma. Establishing the correct diagnosis is mandatory for choosing the appropriate
254 management (**Figure 2**) and, when surgery is indicated, this option is safe and effective with
255 few complications and no recurrences.

256 **References**

- 257 1. Jackler RK, Driscoll CLW. *Tumors of the Ear and Temporal Bone* by Robert K.
258 *Jackler*. 2000.
- 259 2. Saito H, Baxter A. Undiagnosed intratemporal facial nerve neurilemmomas. *Arch*
260 *Otolaryngol*. 1972;95(5):415-9.
- 261 3. Lahlou G, Nguyen Y, Russo FY, et al. Intratemporal facial nerve schwannoma: clinical
262 presentation and management. *Eur Arch Otorhinolaryngol*. December 2015.
- 263 4. Mangham C, Carberry JN, Brackmann DE. Management of intratemporal vascular
264 tumors. *Laryngoscope*. 1981;91(6):867-76.
- 265 5. Bernardeschi D, Dunnebier EA, Sauvaget E, et al. Vascular malformation (so-called
266 hemangioma) of Scarpa's ganglion. *Acta Otolaryngol*. 2004;124(9):1099-102.
- 267 6. Collin M, Bernardeschi D, Cazals-Hatem D, et al. Meningioma of geniculate ganglion:
268 case report and review of the literature. *Acta Otolaryngol*. 2013;133(3):228-32.
- 269 7. Magliulo G, Alla FR, Colicchio G, et al. Geniculate Ganglion Meningioma. *Skull Base*.
270 2010;20(3):185-8.
- 271 8. Nager G. *Pathology of the Ear and Temporal Bone*. Williams W. Baltimore; 1993.
- 272 9. McRackan T, Wilkinson E, Brackmann D, et al. Stereotactic Radiosurgery for Facial
273 Nerve Schwannomas: Meta-analysis and Clinical Review. *Otol Neurotol*.
274 2015;36(3):393-8.
- 275 10. House J, Brackmann D. Facial nerve grading system. *Otolaryngol Head Neck surg*.
276 1985;93(2):146-7.
- 277 11. Bernardeschi D, Meskine N, Otaibi N, et al. Use of bone anchoring device in
278 electromagnetic computer-assisted navigation in lateral skull base surgery. *Acta*
279 *Otolaryngol*. 2013;133(10):1047-52.

- 280 12. Bernardeschi D, Meskine N, Otaibi N Al, et al. Continuous facial nerve stimulating
281 burr for otologic surgeries. *Otol Neurotol*. 2011;32(8):1347-51.
- 282 13. Semaan MT, Slattery WH, Brackmann DE. Genuiculate ganglion hemangiomas: clinical
283 results and long-term follow-up. *Otol Neurotol*. 2010;31(4):665-70.
- 284 14. Isaacson B, Telian S, McKeever PE, et al. Hemangiomas of the genuiculate ganglion.
285 *Otol Neurotol*. 2005;26(4):796-802.
- 286 15. Oldenburg MS, Carlson ML, Abel KM Van, et al. Management of Genuiculate Ganglion
287 Hemangiomas Case Series and Systematic Review of the Literature. *Otol Neurotol*.
288 2015;36(10):1735-40.
- 289 16. Ylikoski J, Brackmann DE, Savolainen S. Pressure neuropathy of the facial nerve: A
290 case report with light and electron microscopic findings. *J Laryngol Otol*.
291 1984;98(9):909-14.
- 292 17. Balkany T, Fradis M, Jafek B, et al. Hemangioma of the facial nerve: role of the
293 genuiculate capillary plexus. *Skull Base Surg*. 1991;1(1):59-63.
- 294 18. O'Donoghue G. Tumors of the facial nerve. *Neurotol Mosby, St Louis*. 1994:1323-4.
- 295 19. Friedman O, Neff BA, Willcox TO, et al. Temporal bone hemangiomas involving the
296 facial nerve. *Otol Neurotol*. 2002;23(5):760-6.
- 297 20. Wilkinson E, Hoa M, Slattery W 3rd, et al. Evolution in the management of facial
298 nerve schwannoma. *Laryngoscope*. 2011;121(10):2065-74.
- 299 21. Bacciu A, Nusier A, Lauda L, et al. Are the Current Treatment Strategies for Facial
300 Nerve Schwannoma Appropriate Also for Complex Cases ? *Audiol Neurotol*.
301 2013;18(3):184-91.
- 302 22. Sherman J, Dagnew E, Pensak M, et al. Facial Nerve Neuromas : Report of 10 Cases
303 and Review of the Literature. *Neurosurgery*. 2002;50(3):450-6.

- 304 23. Angeli SI, Brackmann DE, Angeles L. Is surgical excision of facial nerve
305 schwannomas always indicated ? *Otolaryngol Head Neck Surg.* 1997;117(6):144-7.
- 306 24. Perez R, Chen JM, Nedzelski JM. Intratemporal facial nerve schwannoma: a
307 management dilemma. *Otol Neurotol.* 2005;26(1):121-6.
- 308 25. Lee JD, Kim SH, Song MH, et al. Management of facial Nerve Schwannoma in
309 Patients With Favorable Facial Function. *Laryngoscope.* 2007;117(6):1063-8.
- 310 26. Wang K, Chou H, Li Y. Facial nerve hemangiomas at geniculate ganglion:
311 preservation of nerve integrity is correlated with duration of facial palsy. *Am J*
312 *Otolaryngol.* 2015;36(2):264-7.
- 313 27. Luetje CM, Syms CA, Luxford WE, et al. Meningiomas intrinsic to the geniculate
314 ganglion. *Am J Otol.* 1997;18(3):393-7.
- 315 28. Kida Y, Yoshimoto M, Hasegawa T. Radiosurgery for Facial Schwannoma. *J*
316 *Neurosurg.* 2007;106(1):24-9.
- 317 29. Jacob J, Driscoll C, Link M. Facial nerve schwannomas of the Cerebellopontine Angle:
318 The Mayo Clinic Experience. *J Neurol Surg B Skull Base.* 2012;73(4):230-5.
- 319 30. Moon J, Chang W, Jung H, et al. Gamma knife surgery for facial nerve schwannomas.
320 *J Neurosurg.* 2014;121 Suppl:116-22.
- 321 31. Hasegawa T, Kato T, Kida Y, et al. Gamma Knife: surgery for patients with facial
322 nerve schwannomas: a multiinstitutional retrospective study in Japan. *J Neurosurg.*
323 2016;124(2) :403-10.
- 324 32. Martin N, Sterkers O, Nahum H. Haemangioma of the petros bone : MRI.
325 *Neuroradiology.* 1992 ;34(5) :420-2.
- 326 33. Jäger L, Reiser M. CT and MR imaging of the normal and pathologic conditions of the
327 facial nerve. *Eur J Radiol.* 2001 ;40(2) :133-46.

Patient	Age (year)	Tumor	Tumor size (mm)	Duration of FN palsy (months)	FN management	HB pre	HB post	PTA pre (dB)	PTA post (dB)	FU (year)
1	46	Hem	7.7	4	FNG	IV	III	11	16	1.5
2	28	Hem	4	12	FNG	V	III	10	7	3.3
3	46	Hem	8	15	FNG	III	III	10	14	1.3
4	22	Hem	15	22	FNG	V	III	5	9	3.4
5	58	Hem	13	24	FNG	VI	IV	10	10	3.9
6	53	Hem	6	32	FNG	V	LFU	5	LFU	LFU
7	32	Hem	5	39	FNG	VI	IV	5	10	1.2
8	30	Hem	10	50	FNG	V	III	34	41	11.2
9	47	Hem	4	60	FNG	VI	V	5	15	1.3
10	55	Hem	9	250	FNG	IV	III	5	10	2
11	35	Schw	15	2	FNG	II	III	20	20	4.9
12	68	Schw	13	5	FNG	IV	IV	53	101	1
13	24	Schw	10	8	FNG	IV	III	15	18	5.4
14	41	Schw	15	12	Dissection	IV	III	24	21	9.3
15	50	Schw	11	26	FNG	IV	III	16	16	2
16	37	Schw	30	179	FNG	IV	IV	120	120	5.9
17	48	Men	5	44	FNG	IV	III	10	10	2.6

Table 1: Patients' characteristics.

HB = House and Brackman; Schw = schwannoma; Hem = hemangioma; Men = meningioma; FNG =

Facial nerve graft; FU = follow up; LFU = lost to follow-up

		<i>Total</i>	Hemangioma	Schwannoma	Meningioma	p
		<i>N=17</i>	N=10	N=6	N=1	
Size (mm) (mean ± SD)		<i>11 ± 6.3</i>	<i>8 ± 3.7</i>	<i>16 ± 7.3</i>	<i>5</i>	<i>0.03*</i>
FN function	Grade II	<i>1</i>	<i>0</i>	<i>1</i>	<i>0</i>	<i>0.4</i>
	Grade III	<i>1</i>	<i>1</i>	<i>0</i>	<i>0</i>	<i>1</i>
	Grade IV	<i>8</i>	<i>2</i>	<i>5</i>	<i>1</i>	<i>0.03*</i>
	Grade V	<i>4</i>	<i>4</i>	<i>0</i>	<i>0</i>	<i>0.2</i>
	Grade VI	<i>3</i>	<i>3</i>	<i>0</i>	<i>0</i>	<i>0.2</i>
PTA (dB) (mean ± SD)		<i>21 ± 28</i>	<i>10 ± 8.7</i>	<i>41 ± 41</i>	<i>10</i>	<i>0.007*</i>
Vestibular impairment		<i>7</i>	<i>2</i>	<i>4</i>	<i>1</i>	<i>0.1</i>
Tinnitus		<i>2</i>	<i>0</i>	<i>2</i>	<i>0</i>	<i>0.2</i>

Table 2: Preoperative clinical features of 17 patients who underwent surgery for GG tumor.

PTA = Pure-tone audiometry; * = significant (Fisher and Wilcoxon tests comparing hemangioma to schwannoma).

		Schwannoma	Hemangioma	Meningioma
CT scan		Smooth-walled	Irregular margins	Irregular margins
		Homogenous hypodensity	Intratumoral calcifications	Rare intratumoral
		round or oval-shaped	with honeycomb	calcification
		Hourglass aspect	appearance	
CT scan with contrast		Irregular enhancement	Avid enhancement	Avid enhancement
MRI	T1	Iso or hypointense	Isointense	Iso or hypointense
	T2	Iso or hyperintense	Hyperintense	Iso or hyperintense
	T1 with	Irregular avid	Avid enhancement	Avid enhancement
	contrast	enhancement		

334 **Table 3:** Radiological features for the three more frequent GG tumors ^{6,32,33}

335

336 **Figures Legends**

337

338 **Figure 1:** T1 with contrast MRI showing a GG hemangioma (A), a GG meningioma (B), and
339 a GG schwannoma (C).

340

341 **Figure 2:** Management of geniculate ganglion tumors depending on the tumor type.

342 HB = House and Brackman.

Fig. 1

Fig. 2